{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:23:59Z","timestamp":1791257039922,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in treatment of patients with aggressive lymphomas ranging from chimeric antigen receptor T-cell therapy to combination of antibody\u2013drug conjugates with chemotherapy have improved survival outcomes. Despite these significant advances, patients with relapsed or refractory disease experience high physical and psychological symptom burden, and a substantial proportion still die of their lymphoma. In addition, end-of-life care outcomes are suboptimal with high rates of intensive end-of-life health care use and low rates of timely hospice enrollment. Integrating palliative care concurrently with disease-directed care for this patient population has strong potential to improve their symptom burden, quality of life, and end-of-life care. Multiple factors, including heightened prognostic uncertainty in the setting of relapsed\/refractory disease, pose challenges to timely provision of palliative care. This article reviews benefits of primary and specialty palliative care for patients with relapsed\/refractory aggressive lymphomas and barriers to such care. It also highlights strategies for effectively integrating palliative care for patients with relapsed\/refractory aggressive lymphomas.<\/jats:p>","DOI":"10.1182\/hematology.2020000100","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T22:01:13Z","timestamp":1607119273000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas"],"prefix":"10.1182","volume":"2020","author":[{"given":"Oreofe O.","family":"Odejide","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA; and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2020121621163294600_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2020121621163294600_B2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2020121621163294600_B3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpainsymman.2017.08.030","article-title":"Comparing the palliative care needs of patients with hematologic and solid malignancies","volume":"55","author":"Hochman","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"2020121621163294600_B4","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S2352-3026(15)00111-8","article-title":"Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series","volume":"2","author":"LeBlanc","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020121621163294600_B5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jpainsymman.2010.12.008","article-title":"The symptom burden of patients with hematological malignancy: a cross-sectional observational study","volume":"42","author":"Manitta","year":"2011","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"2020121621163294600_B6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/jpm.2019.0311","article-title":"Illness understanding and advance care planning in patients with advanced lymphoma","volume":"23","author":"Trevino","year":"2020","journal-title":"J Palliat Med"},{"issue":"6","key":"2020121621163294600_B7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.32656","article-title":"Patient\u2013hematologist discordance in perceived chance of cure in hematologic malignancies: a multicenter study","volume":"126","author":"Loh","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"2020121621163294600_B8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/bmt.2015.113","article-title":"Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation","volume":"50","author":"El-Jawahri","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020121621163294600_B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0885-3924(02)00440-2","article-title":"Palliative care: the World Health Organization\u2019s global perspective","volume":"24","author":"Sep\u00falveda","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"13","key":"2020121621163294600_B10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMp1215620","article-title":"Generalist plus specialist palliative care\u2014creating a more sustainable model","volume":"368","author":"Quill","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2020121621163294600_B11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"2020121621163294600_B12","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.2016.16786","article-title":"Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial","volume":"316","author":"El-Jawahri","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"2020121621163294600_B13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA"},{"issue":"8","key":"2020121621163294600_B14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.6004\/jnccn.2017.0132","article-title":"NCCN guidelines insights: palliative care, version 2.2017","volume":"15","author":"Dans","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2020121621163294600_B15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JOP.2016.017897","article-title":"Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary","volume":"13","author":"Ferrell","year":"2017","journal-title":"J Oncol Pract"},{"issue":"14","key":"2020121621163294600_B16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/jama.300.14.1665","article-title":"Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment","volume":"300","author":"Wright","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"2020121621163294600_B17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.2009.25.4672","article-title":"End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences","volume":"28","author":"Mack","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020121621163294600_B18","article-title":"Preferred and actual place of death in haematological malignancies: a report from the UK haematological malignancy research network [published online ahead of print 11 May 2020]","author":"Sheridan","journal-title":"BMJ Support Palliat Care"},{"issue":"3","key":"2020121621163294600_B19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cncr.32549","article-title":"Goals of care discussions for patients with blood cancers: association of person, place, and time with end-of-life care utilization","volume":"126","author":"Odejide","year":"2020","journal-title":"Cancer"},{"issue":"32","key":"2020121621163294600_B20","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial","volume":"35","author":"El-Jawahri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020121621163294600_B21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/cncr.28614","article-title":"Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study","volume":"120","author":"Hui","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"2020121621163294600_B22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamainternmed.2015.6599","article-title":"Timeliness of end-of-life discussions for blood cancers: a national survey of hematologic oncologists","volume":"176","author":"Odejide","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2020121621163294600_B23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.28628","article-title":"Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients","volume":"120","author":"Hui","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"2020121621163294600_B24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/bmjspcare-2013-000578","article-title":"Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma","volume":"5","author":"Howell","year":"2015","journal-title":"BMJ Support Palliat Care"},{"issue":"26","key":"2020121621163294600_B25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621163294600_B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"2020121621163294600_B27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020121621163294600_B28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"2020121621163294600_B29","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020121621163294600_B30","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2016.67.8177","article-title":"Barriers to quality end-of-life care for patients with blood cancers","volume":"34","author":"Odejide","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020121621163294600_B31","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1200\/JOP.2014.001859","article-title":"Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study","volume":"11","author":"LeBlanc","year":"2015","journal-title":"J Oncol Pract"},{"issue":"11","key":"2020121621163294600_B32","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0240","article-title":"Attitudes and beliefs toward supportive and palliative care referral among hematologic and solid tumor oncology specialists","volume":"20","author":"Hui","year":"2015","journal-title":"Oncologist"},{"issue":"6","key":"2020121621163294600_B33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpainsymman.2019.12.373","article-title":"Perspectives regarding hospice services and transfusion access: focus groups with blood cancer patients and bereaved caregivers","volume":"59","author":"Henckel","year":"2020","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"2020121621163294600_B34","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1200\/JOP.2014.001537","article-title":"End-of-life care for blood cancers: a series of focus groups with hematologic oncologists","volume":"10","author":"Odejide","year":"2014","journal-title":"J Oncol Pract"},{"issue":"12","key":"2020121621163294600_B35","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1001\/jamainternmed.2014.5271","article-title":"Communication about serious illness care goals: a review and synthesis of best practices","volume":"174","author":"Bernacki","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2020121621163294600_B36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1089\/jpm.2017.0509","article-title":"The surprise question and identification of palliative care needs among hospitalized patients with advanced hematologic or solid malignancies","volume":"21","author":"Hudson","year":"2018","journal-title":"J Palliat Med"},{"key":"2020121621163294600_B37"},{"issue":"6","key":"2020121621163294600_B38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamainternmed.2019.0077","article-title":"Effect of the serious illness care program in outpatient oncology: a cluster randomized clinical trial","volume":"179","author":"Bernacki","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2020121621163294600_B39","doi-asserted-by":"crossref","first-page":"e844","DOI":"10.1200\/JOP.2016.018796","article-title":"REMAP: a framework for goals of care conversations","volume":"13","author":"Childers","year":"2017","journal-title":"J Oncol Pract"},{"issue":"12","key":"2020121621163294600_B40","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(16)30577-0","article-title":"Referral criteria for outpatient specialty palliative cancer care: an international consensus","volume":"17","author":"Hui","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020121621163294600_B41","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2016.03.006","article-title":"Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients","volume":"22","author":"Loggers","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15 suppl","key":"2020121621163294600_B42","doi-asserted-by":"crossref","first-page":"12000","DOI":"10.1200\/JCO.2020.38.15_suppl.12000","article-title":"Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML) [abstract]","volume":"38","author":"El-Jawahri","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/148\/1794843\/hem2020000100c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/148\/1794843\/hem2020000100c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:12:24Z","timestamp":1608297144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/148\/474331\/Strategies-for-introducing-palliative-care-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000100","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}